Salsalate shows efficacy as add-on treatment in diabetes

07/2/2013 | InternalMedicineNews.com (free registration)

Research on patients with poorly controlled type 2 diabetes revealed those who used oral salsalate as an add-on to one to three diabetes drugs attained lower A1C rates at 48 weeks than those in the placebo group. Data also showed 41% of those in the salsalate group attained 0.5 percentage points or greater reductions in A1C at the study's conclusion, compared with 23% of those who took a placebo. The findings appear in the Annals of Internal Medicine.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY